Patents by Inventor Shihong PENG

Shihong PENG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • POLYMORPH OF EP4 RECEPTOR ANTAGONIST, PREPARATION METHOD THEREFOR AND USE THEREOF
    Publication number: 20230074179
    Abstract: Provided are a polymorph of an EP4 receptor antagonist, a preparation method therefor and a use thereof, relating in particular to a polymorph of an EP4 receptor antagonist (S)-4-(1-(2-(4-fluorobenzyl)-4, 7-dihydro-5H-thieno [2,3-c]pyran-3-carboxamido) ethyl) benzoic acid, a preparation method therefor and a use thereof.
    Type: Application
    Filed: January 29, 2021
    Publication date: March 9, 2023
    Inventors: Hankun ZHANG, Junjie YANG, Mingyao LIU, Wenbo ZHOU, Shihong PENG, Huang CHEN, Jian LU
  • Cancer treatment method using ailanthone compounds
    Patent number: 10420747
    Abstract: A pharmaceutical composition comprising an ailanthone (AIL) compound or a derivative thereof, for the treatment of diseases or conditions caused by, dependent from, or associated with excessive androgen receptor activity. Ailantone compounds have been discovered to be a potent inhibitor of both full-length AR (AR-FL) and constitutively-active truncated AR splice variants (AR-Vs), and are found to possess favorable drug-like properties such as good bioavailability, high solubility, lack of CYP inhibition, and low hepatotoxicity. Methods of treatment are also provided.
    Type: Grant
    Filed: November 9, 2016
    Date of Patent: September 24, 2019
    Assignee: EAST CHINA NORMAL UNIVERSITY
    Inventors: Zhengfang Yi, Shihong Peng, Yundong He, Wenbo Zhou, Yihua Chen, Mingyao Liu
  • CANCER TREATMENT METHOD USING AILANTHONE COMPOUNDS
    Publication number: 20180125814
    Abstract: A pharmaceutical composition comprising an ailanthone (AIL) compound or a derivative thereof, for the treatment of diseases or conditions caused by, dependent from, or associated with excessive androgen receptor activity. Ailantone compounds have been discovered to be a potent inhibitor of both full-length AR (AR-FL) and constitutively-active truncated AR splice variants (AR-Vs), and are found to possess favorable drug-like properties such as good bioavailability, high solubility, lack of CYP inhibition, and low hepatotoxicity. Methods of treatment are also provided.
    Type: Application
    Filed: November 9, 2016
    Publication date: May 10, 2018
    Inventors: Zhengfang YI, Shihong PENG, Yundong HE, Wenbo Zhou, Yihua Chen, Mingyao Liu